AGC Biologics acquires AstraZeneca commercial biomanufacturing facility
.jpg)
The Boulder, Colorado, USA facility will increase global capacity and extend manufacturing scale.
AGC Biologics, a global biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has purchased a state-of-the-art commercial manufacturing facility — formerly owned by AstraZeneca — in Boulder, Colorado, USA.
The large-scale biopharmaceutical manufacturing facility houses two 20,000-L (total volume) stainless steel mammalian cell bioreactors. It also has more than 20 acres with multiple opportunities for future expansions, including space for up to four more 20,000-L bioreactors. The automated facility is particularly well suited for high volume commercial production and high titer antibody processes.
AGC Biologics is rapidly expanding its customer portfolio, including a higher ratio of late-phase and commercial projects, as well as advancing current projects into the commercial phase. This addition to their facility network will enable the company to support a wider range of commercial demand.
In addition to this facility acquisition, AGC Biologics is completing major facility expansion projects at its Seattle, Copenhagen and Chiba facilities in 2020 and early 2021. The facility is expected to begin full-scale operations and manufacturing by April 2021.
Related News
-
News Novartis signs US$3.2 bn subcutaneous delivery deal with Alteogen
Swiss pharma giant secures access to Korean biotech's ALT-B4 hyaluronidase platform in milestone-heavy agreement, marking Alteogen's fourth major licensing deal of 2026 as competition intensifies in the subcutaneous drug delivery space.
-
News Women in Pharma: The philosophy of pharmaceutical leadership
In this latest instalment of our Women in Pharma series, we sit down with Clarissa Sowemimo-Coker, Chief Strategy Officer at Ambrose Healthcare and CPHI Middle East Advisory Board Member.
-
News The PSCI Supplier Partnership - Collaboration for Responsible Supply Chains
About the Pharmaceutical Supply Chain Initiative The Pharmaceutical Supply Chain Initiative (PSCI) is the leading, member-led association for pharmaceutical companies working collaboratively to build responsible supply chains. Founded in 2006 and es... -
News AstraZeneca shares plunge 8.9% after reports of BMS talks
Britain's largest drugmaker lost more than GBP£17 billion in market value following reports of preliminary merger discussions with Bristol Myers Squibb that could create a pharmaceutical giant worth nearly US$400 billion, though investors rem... -
News GSK announces £400 million investment in new Cambridge R&D centre
Pharmaceutical giant to establish flagship research facility on Cambridge Biomedical Campus as part of strategic pipeline acceleration
-
News The CPHI Sustainability Summit - Where Conversation Becomes Collaboration
The Report Was Never the Destination - “The future of pharmaceutical sustainability won’t be shaped by individual organisations working in isolation. It will be shaped by partnerships, shared expertise and the willingness to work diffe... -
News Trump's generic drug tariffs set to reshape global pharmaceutical supply chains
The US president has announced plans to impose tariffs of up to 200% on imported generic medicines from August 2028, giving manufacturers a two-year window to establish domestic production facilities. The move threatens to upend a global supply chain t... -
News Building Safer, More Responsible Pharmaceutical Supply Chains: PSCI Global Audit Insights
The Pharmaceutical Supply Chain Initiative (PSCI) has released its seventh annual Audit Findings Analysis Report, offering unprecedented insights into supplier practices across the global pharmaceutical and healthcare industry.With a record-breaking 24...